NASDAQ:MYL - Mylan Stock Price, Price Target & More

$40.81 +0.07 (+0.17 %)
(As of 04/19/2018 04:00 PM ET)
Previous Close$40.74
Today's Range$40.34 - $41.24
52-Week Range$29.39 - $47.82
Volume2.71 million shs
Average Volume5.05 million shs
Market Capitalization$21.10 billion
P/E Ratio8.86
Dividend YieldN/A
Beta1.34

About Mylan (NASDAQ:MYL)

Mylan logoMylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty. Its Generics segment primarily develops, manufactures, sells and distributes generic or branded generic pharmaceutical products in tablet, capsule, injectable, transdermal patch, gel, cream or ointment form, as well as API. Its Specialty segment is focused on respiratory and allergy therapies. The EpiPen Auto-Injector, which is used in the treatment of severe allergic reactions, is an epinephrine auto-injector. Its Perforomist Inhalation Solution is a long-acting beta2-adrenergic agonist indicated for the maintenance treatment of bronchoconstriction in chronic obstructive pulmonary disorder (COPD) patients. The Company also markets ULTIVA, which is an analgesic agent.

Receive MYL News and Ratings via Email

Sign-up to receive the latest news and ratings for MYL and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:MYL
CUSIP62853010
Phone44-0-17-0785-3000

Debt

Debt-to-Equity Ratio1.06%
Current Ratio1.13%
Quick Ratio0.73%

Price-To-Earnings

Trailing P/E Ratio8.86
Forward P/E Ratio7.61
P/E Growth1.33

Sales & Book Value

Annual Sales$11.91 billion
Price / Sales1.76
Cash Flow$7.8936 per share
Price / Cash5.17
Book Value$24.81 per share
Price / Book1.64

Profitability

EPS (Most Recent Fiscal Year)$4.56
Net Income$696 million
Net Margins5.84%
Return on Equity19.14%
Return on Assets6.92%

Miscellaneous

Employees35,000
Outstanding Shares514,780,000

How to Become a New Pot Stock Millionaire

Mylan (NASDAQ:MYL) Frequently Asked Questions

What is Mylan's stock symbol?

Mylan trades on the NASDAQ under the ticker symbol "MYL."

How were Mylan's earnings last quarter?

Mylan (NASDAQ:MYL) posted its quarterly earnings results on Wednesday, February, 28th. The company reported $1.43 EPS for the quarter, beating the consensus estimate of $1.41 by $0.02. The business had revenue of $3.24 billion for the quarter, compared to analysts' expectations of $3.29 billion. Mylan had a net margin of 5.84% and a return on equity of 19.14%. Mylan's revenue was down .9% on a year-over-year basis. During the same period in the previous year, the company posted $1.57 EPS. View Mylan's Earnings History.

When is Mylan's next earnings date?

Mylan is scheduled to release their next quarterly earnings announcement on Wednesday, May, 9th 2018. View Earnings Estimates for Mylan.

What guidance has Mylan issued on next quarter's earnings?

Mylan updated its FY18 earnings guidance on Wednesday, April, 11th. The company provided earnings per share (EPS) guidance of $5.20-5.60 for the period, compared to the Thomson Reuters consensus estimate of $5.38. The company issued revenue guidance of $11.75-13.25 billion, compared to the consensus revenue estimate of $12.43 billion.

What price target have analysts set for MYL?

19 analysts have issued 12 month target prices for Mylan's stock. Their forecasts range from $29.39 to $59.00. On average, they expect Mylan's share price to reach $47.2311 in the next twelve months. View Analyst Ratings for Mylan.

What are Wall Street analysts saying about Mylan stock?

Here are some recent quotes from research analysts about Mylan stock:
  • 1. Cantor Fitzgerald analysts commented, "Takeaways from the quarter: 1) The North America segment was down 8%, excluding Epipen, which declined $131.9MM in 4Q17, and $655.4MM in 2017. EU grew 16% in the quarter, and Rest of World grew 12%. 2) Generic drug pricing continued to be a headwind in the U.S. during the quarter. However, favorable pricing on existing products in Europe was a tailwind in 4Q17. 3) The Restasis target action date is in July 2018. The Biosimilar pegfilgrastim target action date is in early June. 4) MYL repurchased 12.4MM shares during 2017, and an additional 9.8MM shares in January 2018. 4) MYL expects to launch generic Adavir and Neulasta in 2018, and has risk-weighted these launches in its 2018 guidance." (3/1/2018)
  • 2. According to Zacks Investment Research, "Mylan received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company being one of the first filers, will also enjoy 180 days of exclusivity. The FDA approval of biosimilar version of Herceptin will also boost the biosimilars portfolio. However, Mylan’s performance in 2017 was impacted by ongoing challenges in North America. The third quarter experienced an accelerated decline in EpiPen sales due to the launch of an authorized generic as well as the contraction of the overall epinephrine auto-injector market. Sales are expected to decline further. Moreover, the complete response letter from the FDA regarding its abbreviated new drug application ANDA for the generic version of asthma drug Advair Diskus was a setback given the market potential. Shares have performed better than the industry in the last one year." (1/16/2018)
  • 3. Argus analysts commented, "junior version" (8/22/2017)

Are investors shorting Mylan?

Mylan saw a decline in short interest in the month of March. As of March 29th, there was short interest totalling 17,578,475 shares, a decline of 14.1% from the March 15th total of 20,463,110 shares. Based on an average daily volume of 4,309,865 shares, the days-to-cover ratio is presently 4.1 days. Currently, 3.6% of the company's shares are short sold.

Who are some of Mylan's key competitors?

Has Mylan been receiving favorable news coverage?

Media headlines about MYL stock have trended somewhat positive on Thursday, according to Accern Sentiment Analysis. The research group identifies positive and negative news coverage by analyzing more than 20 million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Mylan earned a media sentiment score of 0.07 on Accern's scale. They also gave news coverage about the company an impact score of 45.82 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the stock's share price in the next several days.

How do I buy shares of Mylan?

Shares of MYL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Mylan's stock price today?

One share of MYL stock can currently be purchased for approximately $40.81.

How big of a company is Mylan?

Mylan has a market capitalization of $21.10 billion and generates $11.91 billion in revenue each year. The company earns $696 million in net income (profit) each year or $4.56 on an earnings per share basis. Mylan employs 35,000 workers across the globe.

How can I contact Mylan?

Mylan's mailing address is BUILDING 4 TRIDENT PLACE MOSQUITO WAY, HATFIELD X0, AL10 9UL. The company can be reached via phone at 44-0-17-0785-3000 or via email at [email protected]


MarketBeat Community Rating for Mylan (MYL)

Community Ranking:  2.9 out of 5 (star star)
Outperform Votes:  592 (Vote Outperform)
Underperform Votes:  426 (Vote Underperform)
Total Votes:  1,018
MarketBeat's community ratings are surveys of what our community members think about Mylan and other stocks. Vote "Outperform" if you believe MYL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe MYL will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Mylan (NASDAQ:MYL) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
19 Wall Street analysts have issued ratings and price targets for Mylan in the last 12 months. Their average twelve-month price target is $47.2311, suggesting that the stock has a possible upside of 15.73%. The high price target for MYL is $59.00 and the low price target for MYL is $29.39. There are currently 5 hold ratings and 14 buy ratings for the stock, resulting in a consensus rating of "Buy."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyBuy
Consensus Rating Score: 2.742.682.612.61
Ratings Breakdown: 0 Sell Rating(s)
5 Hold Rating(s)
14 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
6 Hold Rating(s)
13 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
7 Hold Rating(s)
11 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $47.2311$46.81$44.2994$40.9619
Price Target Upside: 15.73% upside11.40% upside5.30% downside6.37% upside

Mylan (NASDAQ:MYL) Consensus Price Target History

Price Target History for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/12/2018JPMorgan ChaseSet Price TargetBuy$53.00LowView Rating Details
4/12/2018Leerink SwannUpgradeMarket Perform -> Outperform$44.00LowView Rating Details
4/11/2018Cantor FitzgeraldSet Price TargetHold$41.00MediumView Rating Details
4/9/2018Morgan StanleySet Price TargetBuy$50.00HighView Rating Details
4/3/2018Royal Bank of CanadaSet Price TargetHold$45.00LowView Rating Details
3/15/2018MizuhoBoost Price TargetBuy$45.00 -> $51.00LowView Rating Details
3/1/2018UBSSet Price TargetBuy$54.00HighView Rating Details
1/25/2018Susquehanna BancsharesReiterated RatingPositive -> Positive$47.00 -> $55.00LowView Rating Details
1/24/2018Deutsche BankSet Price TargetBuy$50.00LowView Rating Details
1/18/2018Wells FargoSet Price TargetHold$33.00 -> $43.00LowView Rating Details
1/11/2018Goldman SachsBoost Price TargetBuy$46.00 -> $52.00HighView Rating Details
1/4/2018CitigroupReiterated RatingBuy -> Buy$48.00 -> $58.00HighView Rating Details
12/12/2017GuggenheimInitiated CoverageBuy -> Buy$59.00LowView Rating Details
10/5/2017InstinetReiterated RatingBuy$37.00N/AView Rating Details
10/5/2017CowenReiterated RatingMarket Perform$30.00 -> $36.00N/AView Rating Details
10/4/2017BTIG ResearchBoost Price TargetBuy -> Buy$42.00 -> $45.00HighView Rating Details
9/29/2017BMO Capital MarketsReiterated RatingBuy$45.00LowView Rating Details
8/22/2017ArgusDowngradeBuy -> Hold$47.59 -> $29.39LowView Rating Details
5/22/2017BarclaysUpgradeEqual Weight -> Overweight$47.00 -> $50.00LowView Rating Details
12/30/2016Stifel NicolausReiterated RatingPositiveN/AView Rating Details
10/10/2016Raymond JamesUpgradeMarket Perform -> Strong-Buy$57.00N/AView Rating Details
9/23/2016Sanford C. BernsteinSet Price TargetBuy$60.00N/AView Rating Details
8/26/2016Evercore ISIReiterated RatingHold$49.00N/AView Rating Details
8/24/2016Bank of AmericaReiterated RatingBuy$70.00N/AView Rating Details
(Data available from 4/19/2016 forward)

Earnings

Mylan (NASDAQ:MYL) Earnings History and Estimates Chart

Earnings by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ:MYL) Earnings Estimates

2018 EPS Consensus Estimate: $5.40
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20181$0.92$0.92$0.92
Q2 20181$1.22$1.22$1.22
Q3 20181$1.46$1.46$1.46
Q4 20181$1.80$1.80$1.80

Mylan (NASDAQ MYL) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2018$1.07N/AView Earnings Details
2/28/2018Q4 2017$1.41$1.43$3.2910 billion$3.2390 billionViewListenView Earnings Details
11/6/2017Q3 2017$1.20$1.10$3.0927 billion$2.9871 billionViewN/AView Earnings Details
8/9/2017Q2 2017$1.18$1.10$2.9975 billion$2.9622 billionViewListenView Earnings Details
5/10/2017Q1 17$0.92$0.93$2.8130 billion$2.7195 billionViewN/AView Earnings Details
3/1/2017Q4 2016$1.42$1.57$3.1754 billion$3.2678 billionViewN/AView Earnings Details
11/9/2016Q3 2016$1.50$1.38$3.12 billion$3.06 billionViewListenView Earnings Details
8/9/2016Q216$1.13$1.16$2.58 billion$2.56 billionViewN/AView Earnings Details
5/3/2016Q116$0.74$0.76$2.23 billion$2.19 billionViewN/AView Earnings Details
2/10/2016Q415$1.27$1.22$2.71 billion$2.4907 billionViewListenView Earnings Details
10/30/2015Q315$1.38$1.43$2.79 billion$2.71 billionViewListenView Earnings Details
8/6/2015Q215$0.89$0.91$2.39 billion$2.37 millionViewN/AView Earnings Details
5/5/2015Q115$0.70$0.70$2.2220 billion$1.8717 billionViewListenView Earnings Details
3/2/2015Q414$1.05$1.05$2.07 billion$2.08 billionViewListenView Earnings Details
10/30/2014Q314$1.14$1.16$2.06 billion$2.08 billionViewN/AView Earnings Details
8/7/2014Q214$0.70$0.69$1.88 billion$1.84 billionViewN/AView Earnings Details
5/1/2014Q114$0.63$0.66$1.80 billion$1.72 billionViewN/AView Earnings Details
2/27/2014Q413$0.75$0.78$1.81 billion$1.81 billionViewN/AView Earnings Details
10/31/2013Q313$0.79$0.82$1.84 billion$1.77 billionViewN/AView Earnings Details
8/1/2013Q2 2013$0.67$0.68$1.73 billion$1.70 billionViewN/AView Earnings Details
5/2/2013Q1 2013$0.62$0.62$1.6939 billion$1.6315 billionViewN/AView Earnings Details
2/27/2013Q4 2012$0.64$0.65$1.73 billion$1.72 billionViewN/AView Earnings Details
10/25/2012$0.77$0.83ViewN/AView Earnings Details
7/26/2012$0.55$0.60ViewN/AView Earnings Details
4/26/2012$0.51$0.52ViewN/AView Earnings Details
2/21/2012$0.50$0.53ViewN/AView Earnings Details
10/26/2011$0.51$0.55ViewN/AView Earnings Details
7/27/2011$0.45$0.52ViewN/AView Earnings Details
5/3/2011$0.44$0.44ViewN/AView Earnings Details
2/24/2011$0.45$0.45ViewN/AView Earnings Details
10/26/2010Q3 2010$0.42$0.43ViewN/AView Earnings Details
7/28/2010Q2 2010$0.38$0.37ViewN/AView Earnings Details
4/29/2010Q1 2010$0.34$0.36ViewN/AView Earnings Details
2/25/2010Q4 2009$0.30$0.33ViewN/AView Earnings Details
10/29/2009Q3 2009$0.27$0.32ViewN/AView Earnings Details
7/30/2009Q2 2009$0.29$0.32ViewN/AView Earnings Details
4/30/2009Q1 2009$0.27$0.22ViewN/AView Earnings Details
2/19/2009Q4 2008$0.14$0.26ViewN/AView Earnings Details
10/30/2008Q3 2008$0.12$0.23ViewN/AView Earnings Details
8/6/2008Q2 2008$0.10$0.16ViewN/AView Earnings Details
5/8/2008Q1 2008$0.08$0.09ViewN/AView Earnings Details
2/27/2008Q4 2007($0.06)$0.11ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Mylan (NASDAQ:MYL) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Mylan (NASDAQ MYL) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.69%
Institutional Ownership Percentage: 84.53%
Insider Trading History for Mylan (NASDAQ:MYL)
Institutional Ownership by Quarter for Mylan (NASDAQ:MYL)

Mylan (NASDAQ MYL) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/6/2018Paul CampbellInsiderSell7,030$44.01$309,390.3017,054View SEC Filing  
3/6/2018Robert J. CouryDirectorSell50,000$43.41$2,170,500.00View SEC Filing  
3/2/2018Anthony MauroInsiderSell12,257$40.35$494,569.95147,435View SEC Filing  
3/2/2018Rajiv MalikPresidentSell50,000$40.91$2,045,500.00503,751View SEC Filing  
3/2/2018Robert J. CouryDirectorSell150,000$40.10$6,015,000.00View SEC Filing  
1/9/2018Heather M. BreschCEOSell75,000$45.00$3,375,000.00View SEC Filing  
6/9/2017Anthony MauroInsiderSell10,000$40.00$400,000.00140,653View SEC Filing  
6/9/2017Rajiv MalikPresidentSell25,000$40.00$1,000,000.00799,855View SEC Filing  
3/23/2017Laboratories AbbottMajor ShareholderSell44,000,000$41.60$1,830,400,000.00View SEC Filing  
8/9/2016Heather M BreschCEOSell100,200$50.00$5,010,000.00828,318View SEC Filing  
6/3/2016Joseph C Md MaroonDirectorBuy1,670$44.95$75,066.5022,036View SEC Filing  
5/25/2016Robert J CindrichDirectorBuy1,190$42.47$50,539.3013,384View SEC Filing  
5/12/2016Melina E HigginsDirectorBuy19,900$38.68$769,732.001,872View SEC Filing  
5/6/2016Melina E HigginsDirectorBuy100$38.69$3,869.001,872View SEC Filing  
4/28/2016Melina E HigginsDirectorBuy35,000$42.92$1,502,200.00View SEC Filing  
4/5/2016Robert J CouryChairmanSell217,755$45.96$10,008,019.801,334,306View SEC Filing  
3/31/2016Joseph C Md MaroonDirectorBuy4,337$46.36$201,063.3216,124View SEC Filing  
3/17/2016Mark W ParrishDirectorBuy1,705$44.00$75,020.0031,365View SEC Filing  
3/8/2016Wendy CameronDirectorBuy2,190$45.69$100,061.1066,677View SEC Filing  
3/3/2016Robert J CindrichDirectorBuy2,187$45.83$100,230.2110,322View SEC Filing  
12/17/2015John D. SheehanCFOSell34,579$55.03$1,902,882.37171,251View SEC Filing  
6/15/2015Melina E HigginsDirectorSell8,351$73.08$610,291.08View SEC Filing  
2/3/2015Anthony MauroInsiderSell13,255$53.15$704,503.25View SEC Filing  
2/3/2015Heather M BreschCEOSell411,996$53.15$21,897,587.40View SEC Filing  
2/3/2015Rajiv MalikPresidentSell285,394$53.15$15,168,691.10View SEC Filing  
2/3/2015Robert J CouryChairmanSell947,119$52.55$49,771,103.45View SEC Filing  
2/3/2015Rodney L PiattDirectorSell46,000$53.15$2,444,900.00View SEC Filing  
11/26/2014John D SheehanCFOSell19,475$57.50$1,119,812.50View SEC Filing  
11/25/2014Heather M BreschCEOSell100,000$55.80$5,580,000.00View SEC Filing  
11/25/2014Rajiv MalikPresidentSell120,000$55.78$6,693,600.00View SEC Filing  
11/25/2014Robert J CouryChairmanSell165,700$55.78$9,242,746.00View SEC Filing  
11/24/2014Heather M BreschCEOSell80,222$55.86$4,481,200.92View SEC Filing  
11/24/2014Rajiv MalikPresidentSell84,300$55.86$4,708,998.00View SEC Filing  
11/24/2014Robert J CouryChairmanSell105,800$55.88$5,912,104.00View SEC Filing  
11/7/2014Melina E HigginsDirectorBuy14,000$52.45$734,300.00View SEC Filing  
9/18/2014Neil F DimickDirectorSell5,432$48.26$262,148.32View SEC Filing  
6/19/2014Neil F DimickDirectorSell5,432$50.81$275,999.92View SEC Filing  
4/22/2014Rajiv MalikPresidentSell80,000$50.00$4,000,000.00289,117View SEC Filing  
4/14/2014Heather BreschCEOSell75,000$46.07$3,455,250.00293,418View SEC Filing  
3/20/2014Neil DimickDirectorSell5,813$53.08$308,554.0432,136View SEC Filing  
3/14/2014C ToddDirectorSell10,000$53.00$530,000.0023,389View SEC Filing  
3/6/2014Harry KormanCOOSell31,970$54.54$1,743,643.80133,373View SEC Filing  
3/3/2014Anthony MauroInsiderSell20,000$54.81$1,096,200.0025,473View SEC Filing  
3/3/2014Daniel Rizzo, Jr.CAOSell8,003$55.50$444,166.5082,296View SEC Filing  
3/3/2014Douglas LeechDirectorSell10,000$55.40$554,000.0036,271View SEC Filing  
1/2/2014Neil DimickDirectorSell5,813$43.15$250,830.9532,136View SEC Filing  
12/19/2013Rodney PiattDirectorSell10,000$41.84$418,400.0062,436View SEC Filing  
12/12/2013Daniel Rizzo, Jr.CAOSell70,683$42.04$2,971,513.3268,971View SEC Filing  
12/12/2013Melina HigginsDirectorBuy5,000$42.03$210,150.00View SEC Filing  
9/6/2013Heather M BreschCEOSell160,000$35.35$5,656,000.00View SEC Filing  
6/3/2013Neil F DimickDirectorSell19,994$30.51$610,016.94View SEC Filing  
11/27/2012Daniel C Rizzo JrCAOSell161,124$27.28$4,395,462.72View SEC Filing  
11/2/2012Douglas J LeechDirectorSell44,280$25.94$1,148,623.20View SEC Filing  
11/1/2012Anthony MauroInsiderSell12,301$25.79$317,242.79View SEC Filing  
10/5/2012Anthony MauroInsiderSell12,296$24.84$305,432.64View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Mylan (NASDAQ MYL) News Headlines

Source:
DateHeadline
Mylan NV Could Be Closer to a Breakout Than Most Traders RealizeMylan NV Could Be Closer to a Breakout Than Most Traders Realize
investorplace.com - April 19 at 2:51 PM
Mylan (MYL) Receives Consensus Recommendation of "Buy" from BrokeragesMylan (MYL) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 19 at 11:51 AM
[$$] Drugmakers take unorthodox route to boosting biosimilars[$$] Drugmakers take unorthodox route to boosting biosimilars
finance.yahoo.com - April 18 at 5:11 PM
Canada seeks US help to solve EpiPen shortageCanada seeks US help to solve EpiPen shortage
www.reuters.com - April 18 at 8:55 AM
Canada seeks U.S. help to solve EpiPen shortageCanada seeks U.S. help to solve EpiPen shortage
finance.yahoo.com - April 18 at 8:55 AM
Q4 2018 EPS Estimates for Mylan (MYL) Raised by AnalystQ4 2018 EPS Estimates for Mylan (MYL) Raised by Analyst
www.americanbankingnews.com - April 18 at 8:39 AM
UPDATE 1-Canada says working with US FDA to address EpiPen shortageUPDATE 1-Canada says working with US FDA to address EpiPen shortage
www.reuters.com - April 17 at 5:22 PM
Canada says working with U.S. FDA to address EpiPen shortageCanada says working with U.S. FDA to address EpiPen shortage
finance.yahoo.com - April 17 at 5:22 PM
Q4 2018 EPS Estimates for Mylan Lowered by Analyst (MYL)Q4 2018 EPS Estimates for Mylan Lowered by Analyst (MYL)
www.americanbankingnews.com - April 16 at 2:33 AM
$2.79 Billion in Sales Expected for Mylan (MYL) This Quarter$2.79 Billion in Sales Expected for Mylan (MYL) This Quarter
www.americanbankingnews.com - April 15 at 6:59 AM
EpiPen shortages seen in Canada, UK but US supply intactEpiPen shortages seen in Canada, UK but US supply intact
www.reuters.com - April 14 at 8:40 AM
Mylan (MYL) Given "Hold" Rating at CowenMylan (MYL) Given "Hold" Rating at Cowen
www.americanbankingnews.com - April 13 at 6:01 PM
Mylan seeks deal for Mercks consumer products unitMylan seeks deal for Merck's consumer products unit
www.cnbc.com - April 13 at 2:52 PM
Mylan aiming for Merck KGaAs consumer unitMylan aiming for Merck KGaA's consumer unit
seekingalpha.com - April 13 at 12:33 PM
Mylan seeks deal for German Mercks consumer products unit: sourcesMylan seeks deal for German Merck's consumer products unit: sources
www.reuters.com - April 13 at 8:45 AM
Mylan seeks deal for German Mercks consumer products unit - sourcesMylan seeks deal for German Merck's consumer products unit - sources
finance.yahoo.com - April 13 at 8:45 AM
Wired News - Mylan to Collaborate with Fujifilm Kyowa Kirin Biologics for Commercializing Biosimilar to Humira(R) (adalimumab)Wired News - Mylan to Collaborate with Fujifilm Kyowa Kirin Biologics for Commercializing Biosimilar to Humira(R) (adalimumab)
finance.yahoo.com - April 13 at 8:45 AM
Q1 2018 Earnings Estimate for Mylan (MYL) Issued By Leerink SwannQ1 2018 Earnings Estimate for Mylan (MYL) Issued By Leerink Swann
www.americanbankingnews.com - April 13 at 8:33 AM
Mylan (MYL) Sees Large Drop in Short InterestMylan (MYL) Sees Large Drop in Short Interest
www.americanbankingnews.com - April 13 at 3:23 AM
$1.04 Earnings Per Share Expected for Mylan (MYL) This Quarter$1.04 Earnings Per Share Expected for Mylan (MYL) This Quarter
www.americanbankingnews.com - April 13 at 1:23 AM
Mylan Fujifilm Kyowa Team Up to Market Humira BiosimilarMylan Fujifilm Kyowa Team Up to Market Humira Biosimilar
www.zacks.com - April 12 at 5:19 PM
Leerink Upgrades Mylan On Barrage Of Catalysts, Diversified PlatformsLeerink Upgrades Mylan On Barrage Of Catalysts, Diversified Platforms
finance.yahoo.com - April 12 at 5:19 PM
Analyst Urges Investors To Buy This Drugmaker's Dip — And They DoAnalyst Urges Investors To Buy This Drugmaker's Dip — And They Do
finance.yahoo.com - April 12 at 5:19 PM
Mylans Stock Gets Bump After Investor DayMylan's Stock Gets Bump After Investor Day
finance.yahoo.com - April 12 at 5:19 PM
Mylan (MYL) Upgraded by Leerink Swann to OutperformMylan (MYL) Upgraded by Leerink Swann to Outperform
www.americanbankingnews.com - April 12 at 10:51 AM
JPMorgan Chase Analysts Give Mylan (MYL) a $53.00 Price TargetJPMorgan Chase Analysts Give Mylan (MYL) a $53.00 Price Target
www.americanbankingnews.com - April 12 at 10:23 AM
Mylan Inks Deal with Mapi Pharma for Multiple Sclerosis DrugMylan Inks Deal with Mapi Pharma for Multiple Sclerosis Drug
finance.yahoo.com - April 12 at 9:09 AM
Mylan Spotlights Diversification at Investor DayMylan Spotlights Diversification at Investor Day
finance.yahoo.com - April 12 at 9:09 AM
Wells Fargo Analysts Give Mylan (MYL) a $30.00 Price TargetWells Fargo Analysts Give Mylan (MYL) a $30.00 Price Target
www.americanbankingnews.com - April 11 at 7:53 PM
Mylan (MYL) Given a $41.00 Price Target at Cantor FitzgeraldMylan (MYL) Given a $41.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - April 11 at 6:14 PM
Investor Day Highlights Durability of Mylans Global PlatformInvestor Day Highlights Durability of Mylan's Global Platform
finance.yahoo.com - April 11 at 5:13 PM
Mylan to Leverage its World-Class Scientific Platform to Develop a Novel Delivery for Meloxicam, a Non-Opioid Pain MedicationMylan to Leverage its World-Class Scientific Platform to Develop a Novel Delivery for Meloxicam, a Non-Opioid Pain Medication
finance.yahoo.com - April 11 at 5:13 PM
Mylan (MYL) Issues FY18 Earnings GuidanceMylan (MYL) Issues FY18 Earnings Guidance
www.americanbankingnews.com - April 11 at 2:19 PM
Mylan (MYL) Rating Reiterated by CowenMylan (MYL) Rating Reiterated by Cowen
www.americanbankingnews.com - April 11 at 1:20 PM
Biosimilar Pipeline Among Areas of Shareholder Focus at Mylans Investor DayBiosimilar Pipeline Among Areas of Shareholder Focus at Mylan's Investor Day
finance.yahoo.com - April 11 at 8:52 AM
Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab)Mylan Partners with Fujifilm Kyowa Kirin Biologics to Commercialize Biosimilar to Humira® (adalimumab)
finance.yahoo.com - April 11 at 8:52 AM
Mylan (MYL) Rating Reiterated by Royal Bank of CanadaMylan (MYL) Rating Reiterated by Royal Bank of Canada
www.americanbankingnews.com - April 10 at 8:23 PM
Mylan acquires marketing rights to multiple sclerosis drugMylan acquires marketing rights to multiple sclerosis drug
finance.yahoo.com - April 10 at 5:16 PM
Mylan to acquire global marketing rights to MS treatment from Israels Mapi PharmaMylan to acquire global marketing rights to MS treatment from Israel's Mapi Pharma
finance.yahoo.com - April 10 at 8:34 AM
Mylan to buy marketing rights to MS treatment from Israels Mapi PharmaMylan to buy marketing rights to MS treatment from Israel's Mapi Pharma
finance.yahoo.com - April 10 at 8:34 AM
Mylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi PharmaMylan to Acquire the Global Marketing Rights to a Once-monthly Glatiramer Acetate Product through an Investment and Partnership with Israeli Company Mapi Pharma
finance.yahoo.com - April 10 at 8:34 AM
Morgan Stanley Reiterates $50.00 Price Target for Mylan (MYL)Morgan Stanley Reiterates $50.00 Price Target for Mylan (MYL)
www.americanbankingnews.com - April 9 at 6:25 PM
RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON FROM MYLANRECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON FROM MYLAN
www.lse.co.uk - April 9 at 5:17 PM
RECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLANRECORDATI ACQUIRES INTERNATIONAL RIGHTS TO CYSTAGON® FROM MYLAN
feeds.benzinga.com - April 9 at 4:09 AM
Mylan (MYL) Stock Rating Upgraded by Zacks Investment ResearchMylan (MYL) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - April 7 at 4:58 PM
Mylan Announces Pricing Of Private Offering Of $1.5 Bln Of Senior NoteMylan Announces Pricing Of Private Offering Of $1.5 Bln Of Senior Note
www.nasdaq.com - April 6 at 8:24 AM
BRIEF-Mylan Extends Debt Maturities With $1.5 Billion Bond OfferingBRIEF-Mylan Extends Debt Maturities With $1.5 Billion Bond Offering
www.reuters.com - April 6 at 8:24 AM
Mylan Strengthens Its Capital Structure by Extending Its Debt Maturities with a Successful $1.5 Billion Bond OfferingMylan Strengthens Its Capital Structure by Extending Its Debt Maturities with a Successful $1.5 Billion Bond Offering
finance.yahoo.com - April 6 at 8:23 AM
Mylan N.V. -- Moodys assigns Baa3 to Mylans offeringMylan N.V. -- Moody's assigns Baa3 to Mylan's offering
finance.yahoo.com - April 4 at 4:37 PM
Royal Bank of Canada Analysts Give Mylan (MYL) a $45.00 Price TargetRoyal Bank of Canada Analysts Give Mylan (MYL) a $45.00 Price Target
www.americanbankingnews.com - April 3 at 3:36 PM

SEC Filings

Mylan (NASDAQ:MYL) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Mylan (NASDAQ:MYL) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Mylan (NASDAQ MYL) Stock Chart for Thursday, April, 19, 2018

Loading chart…

This page was last updated on 4/19/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.